Skip to content
Research Article Open access CC BY 3.0

Effect of Acarbose on the Bioavailability and Pharmacokinetics of Metronidazole in Healthy and Diabetic Subjects

Saad A. Hussain, Haydar A. H. Kurji, Mowafaq M. Ghareeb, Munaf H. Abdulrazzaq

Journal of Pharmaceutical Research International · pp. 41–49 · Published 12 Mar 2012

10.9734/BJPR/2012/1109

Abstract

Although drug interactions with Acarbose are uncommon, there is a possibility for interference with the pharmacokinetic behaviors of concomitantly administered drugs. The present study was designed to evaluate the possible drug interactions between Acarbose and orally administered MTZ. Twelve healthy volunteers and twelve diabetic patients were enrolled in a randomized controlled crossover study. The effect of Acarbose (single 100mg dose) on the pharmacokinetics of MTZ was evaluated, while the effect of multiple doses was evaluated only in diabetic patients. In both groups, 5ml blood samples were collected into plane tubes at 0, 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 12.0, 24.0 and 48.0 hrs; serum levels of MTZ were evaluated using HPLC technique. The results showed that diabetes mellitus significantly altered the pharmacokinetic parameters of orally administered MTZ compared to healthy subjects. Moreover, both single and multiple doses of Acarbose significantly changed the pharmacokinetic parameters of MTZ when used concomitantly. The pharmacokinetics of orally administered MTZ was significantly affected by both diabetes mellitus and concomitant use of single or multiple doses of Acarbose.

Acarbose metronidazole type 2 DM drug interactions.

References (23)

  1. 1 The Effects of Diabetes Mellitus on Pharmacokinetics and Pharmacodynamics in Humans [DOI]
  2. 2 Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study [DOI]
  3. 3 Acarbose: Its Role in the Treatment of Diabetes Mellitus [DOI]
  4. 4 Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions [DOI]
  5. 5 Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients [DOI]
  6. 6 Intestinal effects of α‐glucosidase inhibitors: absorption of nutrients and enterohormonal changes [DOI]
  7. 7 Effect of Starch Malabsorption on Colonic Function and Metabolism in Humans [DOI]
  8. 8 Bioavailability, Pharmacokinetics and Effects of Glipizide in Type 2 Diabetics [DOI]
  9. 9 Reduction of the acute bioavailability of metformin by the α‐glucosidase inhibitor acarbose in normal man [DOI]
  10. 10 Impairment of Absorption of Digoxin by Acarbose [DOI]
  11. 11 Efficacy and safety of acarbose in the treatment of Type 2 diabetes: data from a 2-year surveillance study [DOI]
  12. 12 A possible interaction of potential clinical interest between digoxin and acarbose* [DOI]
  13. 13 An interaction between digoxin and acarbose. [DOI]
  14. 14 A rapid and sensitive HPLC method for the analysis of metronidazole in human plasma: application to single dose pharmacokinetic and bioequivalence studies
  15. 15 Are there different effects of acarbose and voglibose on serum levels of digoxin in a diabetic patient with congestive heart failure? [DOI]
  16. 16 Serum Level Profile and Pharmacokinetic Parameters of Single Oral Dose of Metronidazole in Type II Diabetic Patients [DOI]
  17. 17 Pharmacokinetics and Pharmacodynamics of Extended‐Release Glipizide GITS Compared with Immediate‐Release Glipizide in Patients with Type II Diabetes Mellitus [DOI]
  18. 18 A Risk-Benefit Appraisal of Acarbose in the Management of Non-Insulin-Dependent Diabetes Mellitus [DOI]
  19. 19 The effect of acarbose on the pharmacokinetics of rosiglitazone [DOI]
  20. 20 Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics [DOI]
  21. 21 Probable interaction of warfarin and acarbose [DOI]
  22. 22 Ileus After Administration of Cold Remedy in an Elderly Diabetic Patient Treated with Acarbose. [DOI]
  23. 23 Relationship Between Gastric Emptying and an α-Glucosidase Inhibitor Effect on Postprandial Hyperglycemia in NIDDM Patients [DOI]

Cited by 6

Reappraisal and perspectives of clinical drug–drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus

Ranjeet Prasad Dash, R. Jayachandra Babu, Nuggehally R. Srinivas · Xenobiotica · 2017

Showing 1 of 6 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

17

Page views

0

PDF downloads

8

Outbound clicks

6

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.